Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.
Morimoto S, Oka Y, Tsuboi A, Tanaka Y, Fujiki F, Nakajima H, Hosen N, Nishida S, Nakata J, Nakae Y, Maruno M, Myoui A, Enomoto T, Izumoto S, Sekimoto M, Kagawa N, Hashimoto N, Yoshimine T, Oji Y, Kumanogoh A, Sugiyama H. Morimoto S, et al. Among authors: nakae y. Cancer Sci. 2012 Mar;103(3):408-14. doi: 10.1111/j.1349-7006.2011.02163.x. Epub 2012 Jan 17. Cancer Sci. 2012. PMID: 22126448 Free PMC article.
Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
Nakae Y, Oka Y, Fujiki F, Morimoto S, Kamiya T, Takashima S, Nakata J, Nishida S, Nakajima H, Hosen N, Tsuboi A, Kyo T, Oji Y, Mizuguchi K, Kumanogoh A, Sugiyama H. Nakae Y, et al. Cancer Immunol Immunother. 2015 Jul;64(7):791-804. doi: 10.1007/s00262-015-1683-7. Epub 2015 Apr 3. Cancer Immunol Immunother. 2015. PMID: 25835542 Free PMC article.
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, Chiba Y, Izumoto S, Elisseeva O, Ichinohasama R, Sakamoto J, Morita S, Nakajima H, Takashima S, Nakae Y, Nakata J, Kawakami M, Nishida S, Hosen N, Fujiki F, Morimoto S, Adachi M, Iwamoto M, Oka Y, Yoshimine T, Sugiyama H. Oji Y, et al. Among authors: nakae y. Int J Cancer. 2016 Sep 15;139(6):1391-401. doi: 10.1002/ijc.30182. Epub 2016 May 31. Int J Cancer. 2016. PMID: 27170523 Free PMC article. Clinical Trial.
Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Kitagawa T, Eguchi H, Wada H, Nagano H, Nakata J, Nakae Y, Hosen N, Oji Y, Tanaka T, Kawase I, Kumanogoh A, Sakamoto J, Doki Y, Mori M, Ohkusa T, Tajiri H, Sugiyama H. Nishida S, et al. Among authors: nakae y. J Immunother. 2014 Feb-Mar;37(2):105-14. doi: 10.1097/CJI.0000000000000020. J Immunother. 2014. PMID: 24509173 Free PMC article. Clinical Trial.
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.
Takashima S, Oka Y, Fujiki F, Morimoto S, Nakajima H, Nakae Y, Nakata J, Nishida S, Hosen N, Tatsumi N, Mizuguchi K, Hashimoto N, Oji Y, Tsuboi A, Kumanogoh A, Sugiyama H. Takashima S, et al. Among authors: nakae y. Future Sci OA. 2016 Oct 3;2(4):FSO96. doi: 10.4155/fsoa-2015-0008. eCollection 2016 Dec. Future Sci OA. 2016. PMID: 28116121 Free PMC article.
Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.
Nakata J, Nakae Y, Kawakami M, Morimoto S, Motooka D, Hosen N, Fujiki F, Nakajima H, Hasegawa K, Nishida S, Tsuboi A, Oji Y, Oka Y, Kumanogoh A, Sugiyama H. Nakata J, et al. Among authors: nakae y. Br J Haematol. 2018 Jul;182(2):287-290. doi: 10.1111/bjh.14768. Epub 2017 May 23. Br J Haematol. 2018. PMID: 28542830 Free article. Clinical Trial. No abstract available.
WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H. Oji Y, et al. Among authors: nakae y. Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21. Int J Cancer. 2018. PMID: 29322496
Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
Nishida S, Morimoto S, Oji Y, Morita S, Shirakata T, Enomoto T, Tsuboi A, Ueda Y, Yoshino K, Shouq A, Kanegae M, Ohno S, Fujiki F, Nakajima H, Nakae Y, Nakata J, Hosen N, Kumanogoh A, Oka Y, Kimura T, Sugiyama H. Nishida S, et al. Among authors: nakae y. J Immunother. 2022 Jan 1;45(1):56-66. doi: 10.1097/CJI.0000000000000405. J Immunother. 2022. PMID: 34874330 Free PMC article.
255 results